Blue test tubes arranged in a line, disappearing into the background

Drug news

Stiefel takes world rights to Toctino from Basilea for Chronic Hand Eczema

Read time: 1 mins

Last updated:11th Jun 2012

Published:11th Jun 2012

Source: Pharmawand

Stiefel,a unit of GSK, is gaining exclusive worldwide rights to Toctino (alitretinoin.) from Basilea Pharma. Toctino is commercially available in 14 countries (and approved in an additional 15) for severe Chronic Hand Eczema that is refractory to treatment with potent topical corticosteroids. In the USA, oral alitretinoin is in a Phase III trial. Stiefel will assume responsibility for the development of the product in the USA and take on existing Toctino distribution agreements in Europe, Canada, Mexico, Israel and South Korea.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves perioperative treatment of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable NSCLC

Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab) for the treatment of adult patients with resectable (tumors greater than T4 cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery – otherwise referred to as perioperative therapy, which is used before and after surgery.

3 mins

Drug news

NICE (UK) Positive for latanoprost–netarsudil combination to treat primary open-angle glaucoma or ocular hypertension

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough

1 min

Drug news

Recordati acquires Enjaymo ( sutimlimab) from Sanofi

Recordati announces an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

1 min

See all news